Aktuelle Optionen zur Behandlung der Riesenzellarteriitis

Moosig, Frank; Schmalzing, Marc; Aries, Peer; Henes, Jörg; Lamprecht, Peter; Rech, Jürgen; Witte, Torsten

doi:10.1055/a-0832-3563

Cited by 1 publication

(2 citation statements)

References 23 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…be used especially in patients with high glucocorticoid requirement or in patients where other treatments have failed or were not tolerated (2,10). CYC was efficient in a case series with 31 patients with severe refractory GCA (8).…”

Section: Clinical Practice Has Shown That It Canmentioning

confidence: 99%

“…With respect to therapy, different immunosuppressive therapeutic options exist with glucocorticoids (GC) being the basis of therapy, biologicals like tocilizumab or conventional synthetic DMARDs like methotrexate (6)(7)(8). In the past, corticosteroid-sparing therapy regimens have become increasingly important to minimise the side effects of long-term glucocorticoid therapy, with tocilizumab being the first drug approved in the EU (9)(10)(11)(12). Like most vasculitides, GCA is also characterised by chronicity and relapses, leading to significant overall morbidity and mortality (13).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Joint Vasculitis Registry in German-speaking countries (GeVas): subgroup analysis of 195 GCA patients

Wallmeier,

Arnold,

Tais

et al. 2024

Clinical and Experimental Rheumatology

View full text Add to dashboard Cite

ObjectiveGiant cell arteritis (GCA) is one of the most common forms of vasculitis. There is an abundance of studies which are conducted in a randomised controlled trial setting but limited with respect to cohort size and follow-up time. GeVas is the first large-scale registry for vasculitides in German-speaking countries that enables to evaluate this rare disease. Herein we focus on the subgroup of GCA patients including follow-up data up to one year. MethodsGeVas is a prospective, web-based, multicentre registry for the documentation of organ manifestations, outcomes, and therapy regimens in vasculitides. Recruitment started in June 2019. By April 2023, 15 centres were initiated and have started to enrol patients. ResultsAfter 4 years, 195 GCA-patients were included in the registry, of which 64% were female and 36% were male. The average age was 76 years at the time of recruitment (IQR=69-82). Seventy-nine percent were included in the registry because of a newly diagnosed GCA and 21% because of a relapse. At the first assessment most of the patients (89%) described general symptoms. Thirty-one percent stated ocular symptoms. Cranial symptoms were documented in 78% of the cases. All patients were documented with immunosuppressive treatment at start, of whom 95% received prednisolone, 16% cyclophosphamide, 20% methotrexate, and 48% tocilizumab. After three months 62% and after one year 91% of the patients achieved remission. Conclusion Regarding demographics, clinical manifestations and diagnostics, our study showed a similar composition comparedto other studies. However, our data differed in terms of treatment regimens.

show abstract

Section: Clinical Practice Has Shown That It Canmentioning

confidence: 99%